NEW YORK GENOME CENTER INC: Form 990, tax year 2023
View the entire original 990 at ProPublica ↗
- Organization
- NEW YORK GENOME CENTER INC (EIN 80-0631734)
- Tax period
- 2023-01-01 to 2023-12-31
- Filed
- 2024-11-07
- IRS object ID
- 202413129349302616
- Schema version
- 2023v5.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule L
- Schedule M
- Schedule O
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2024-11-07T11:22:06-06:00 | ReturnTs |
| Tax Period End | 2023-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 135565207 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KPMG LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 345 PARK AVENUE | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 101540102 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2023-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 800631734 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | NEW YORK GENOME CENTER INC | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | NEWY | BusinessNameControlTxt |
| Phone | 6469777000 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 101 AVENUE OF THE AMERICAS 7TH FL | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 100131941 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | MARIA JOANTA | PersonNm |
| Person Title | CHIEF FINANCIAL OFFICER | PersonTitleTxt |
| Phone | 6469777000 | PhoneNum |
| Signature | 2024-11-06 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IRS Responsible Prty Info Curr | 0 | IRSResponsiblePrtyInfoCurrInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | EVAN W SEEKAMP | PreparerPersonNm |
| PTIN | P01907071 | PTIN |
| Phone | 2127589700 | PhoneNum |
| Preparation | 2024-11-05 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2023 | TaxYr |
| Build TS | 2024-10-15 13:58:12Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | TOM MANIATIS | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 101 AVE OF THE AMERICAS | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10013 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $98,230,028 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.NYGENOME.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2010 | FormationYr |
| Legal Domicile State | DE | LegalDomicileStateCd |
| Activity Or Mission | ADVANCING GENOMIC RESEARCH TO DRIVE NOVEL BIOMEDICAL DISCOVERIES TO IMPROVE HUMAN HEALTH. | ActivityOrMissionDesc |
| Voting Members Governing Body | 24 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 23 | VotingMembersIndependentCnt |
| Total Employee | 224 | TotalEmployeeCnt |
| Total Volunteers | 25 | TotalVolunteersCnt |
| Total Gross UBI | $1,634,112 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $53,970,524 | PYContributionsGrantsAmt |
| CY Contributions Grants | $81,695,780 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $11,277,968 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $9,712,534 | CYProgramServiceRevenueAmt |
| PY Investment Income | -$12,410 | PYInvestmentIncomeAmt |
| CY Investment Income | $191,646 | CYInvestmentIncomeAmt |
| PY Other Revenue | $2,665,604 | PYOtherRevenueAmt |
| CY Other Revenue | $1,340,469 | CYOtherRevenueAmt |
| PY Total Revenue | $67,901,686 | PYTotalRevenueAmt |
| CY Total Revenue | $92,940,429 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $2,253,429 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $3,387,586 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $29,302,214 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $33,690,192 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $140 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $14,225 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $1,355,909 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $40,640,090 | PYOtherExpensesAmt |
| CY Other Expenses | $44,780,821 | CYOtherExpensesAmt |
| PY Total Expenses | $72,195,873 | PYTotalExpensesAmt |
| CY Total Expenses | $81,872,824 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$4,294,187 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $11,067,605 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $181,740,451 | TotalAssetsBOYAmt |
| Total Assets EOY | $184,052,230 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $146,891,982 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $138,136,156 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $34,848,469 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $45,916,074 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | OPERATE A STATE-OF-THE-ART, WORLD CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $58,296,070 | ExpenseAmt |
| Grant | $3,387,586 | GrantAmt |
| Revenue | $4,514,112 | RevenueAmt |
| Desc | GENOME SEQUENCING: NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST TEN YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 102,800 WHOLE GENOME SAMPLES. NYGC HAS ACQUIRED TWO OF THE NEWEST ILLUMINA NOVASEQ X SYSTEMS SEQUENCERS, EACH WITH THE CAPACITY TO SEQUENCE TWENTY THOUSAND HUMAN GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. IN ADDITION, NYGC OPERATES AN OXFORD NANOPORE PROMETHION SEQUENCER FOR LONG READ SEQUENCING, AND CONTINUED TO TEST AND VALIDATE A HIGH-THROUGHPUT SEQUENCER FROM ULTIMA GENOMICS (THE UG100). SEE SCHEDULE O. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $7,058,489 | ExpenseAmt |
| Revenue | $5,198,422 | RevenueAmt |
| Desc | CLINICAL SEQUENCING: NYGC IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS THROUGH ITS CLEP/CLIA CERTIFIED CLINICAL LABORATORY: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLEGENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, CONSTITUTIONAL WHOLE EXOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, ONCOLOGY WHOLE EXOME AND TRANSCRIPTOME SEQUENCING, AND THE SMASH GENOMIC ASSAY. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Expenses | $65,354,559 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (1) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | Yes (1) | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | Yes (1) | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | Yes (1) | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | Yes (1) | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 69 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 224 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | Yes (1) | UnrelatedBusIncmOverLimitInd |
| Form990 T Filed | Yes (1) | Form990TFiledInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 24 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 23 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (1) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (1) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | LA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ME | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ND | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| Other Website | Yes (X) | OtherWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | NANCY KONG | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 6469777154 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 101 AVENUE OF THE AMERICAS 7TH FL | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10013 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part VII | Yes (X) | InfoInScheduleOPartVIIInd |
Form990 Part VII Section A Form990PartVIISectionAGrp (39 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| RUSSELL L CARSON MBA | |||||||||
| DIRECTOR & CHAIRMAN | 1.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| IVAN G SEIDENBERG MBA | |||||||||
| DIRECTOR & CO-CHAIR | 1.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| HERB PARDES MD | |||||||||
| DIRECTOR & EXEC. VICE CHAI | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| GORDON F TOMASELLI MD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| BRUCE STILLMAN PHD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| KATRINA ARMSTRONG MD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| SELWYN VICKERS MD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| DENNIS S CHARNEY MD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| DAFNA BAR-SAGI PHD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| KEVIN J TRACEY MD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| KENNETH A DILL PHD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| RICHARD P LIFTON MD PHD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| ROBERT HARRINGTON MD | |||||||||
| DIRECTOR (AS OF 10/23) | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| FRANCIS LEE MD PHD | |||||||||
| DIRECTOR (3/23 TO 10/23) | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| AUGUSTINE M K CHOI MD | |||||||||
| DIRECTOR (THRU 3/23) | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| ELI CASDIN | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| NICHOLAS DONOFRIO | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JOSEPH E EDELMAN | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JOHN B EHRENKRANZ | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| ANTHONY B EVNIN PHD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JOHN P HAVENS | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| WESLIE R JANEWAY | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| FRANK V SICA | |||||||||
| DIRECTOR & COMMITTEE CHAIR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JIM SIMONS PHD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| NANCY THORNBERRY | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| TOM MANIATIS PHD | |||||||||
| SCIENTIFIC DIRECTOR & CEO | 40.00 | 0.00 | Yes (X) | Yes (X) | $659,380 | $0 | $0 | ||
| ELIZABETH BROOKS O'BRIEN | |||||||||
| VP & GENERAL COUNSEL | 40.00 | 0.00 | Yes (X) | $466,101 | $0 | $44,808 | |||
| MARIA JOANTA | |||||||||
| CHIEF FINANCIAL OFFICER | 40.00 | 0.00 | Yes (X) | $385,336 | $0 | $49,938 | |||
| CAROL ASHE | |||||||||
| CHIEF BUSINESS OFFICER | 40.00 | 0.00 | $436,587 | $0 | $19,917 | Yes (X) | |||
| CHARLES GAGNON | |||||||||
| CHIEF INFORMATION OFFICER | 40.00 | 0.00 | $344,112 | $0 | $49,131 | Yes (X) | |||
| THOMAS LEHNER | |||||||||
| SCI DIR, NEURO DIS GEN | 40.00 | 0.00 | $404,554 | $0 | $33,760 | Yes (X) | |||
| SOREN GERMER | |||||||||
| SVP, GENOME TECHNOLOGIES | 40.00 | 0.00 | $437,568 | $0 | $37,446 | Yes (X) | |||
| MICHAEL CHARLES ZODY | |||||||||
| SCIENTIFIC DIR, COMP BIOLO | 40.00 | 0.00 | $369,902 | $0 | $29,110 | Yes (X) | |||
| SARAH LESSER AVINS | |||||||||
| SVP, ADVANCEMENT & CHIEF D | 40.00 | 0.00 | $564,596 | $0 | $37,074 | Yes (X) | |||
| SHAILAJA GARGEYA | |||||||||
| SENIOR DIR, SOFTWARE ENGIN | 40.00 | 0.00 | $332,688 | $0 | $19,917 | Yes (X) | |||
| DAYNA M OSCHWALD | |||||||||
| CHIEF OF STAFF | 40.00 | 0.00 | $282,476 | $0 | $33,972 | Yes (X) | |||
| CHRISTOPHER PHIFER BLACK | |||||||||
| SENIOR DIRECTOR, RESEARCH | 40.00 | 0.00 | $255,308 | $0 | $44,331 | Yes (X) | |||
| HANNAH GOULDING | |||||||||
| SENIOR DIRECTOR, HUMAN RES | 40.00 | 0.00 | $245,119 | $0 | $14,824 | Yes (X) | |||
| CATHERINE E REEVES | |||||||||
| SENIOR DIRECTOR, RESEARCH | 40.00 | 0.00 | $243,210 | $0 | $32,796 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $5,426,937 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $447,024 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 98 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd |
|---|---|---|---|---|---|---|---|---|---|
| DONNELLY MECHANICAL | |||||||||
| 96-59 222ND STREET | QUEENS | NY | 11429 | ENGINEERING SERVICES | $928,790 | ||||
| GUARDIAN SERVICES INDUSTRIES INC | |||||||||
| 88005 EXPEDITE WAY | CHICAGO | IL | 60695 | CLEANING SERVICES | $372,883 | ||||
| STOEKIUS RIGHTS AB | |||||||||
| DATA SERVICES | $292,688 | MARIA PRASTGARDSGATA 28 APT 1401 | STOCKHOLM | SW | 11852 | ||||
| WAYNE CLARKE | |||||||||
| CONSULTING SERVICES | $159,605 | 327 3D ST E SASKATOON | SASKATCHEWAN | CA | S7H 1L4 | ||||
| KPMG LLP | |||||||||
| PO BOX 120511 | DALLAS | TX | 75312 | ACCOUNTING SERVICES | $156,000 | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 55 | CntrctRcvdGreaterThan100KCnt |
| Membership Dues | $2,735,000 | MembershipDuesAmt |
| Government Grants | $22,283,205 | GovernmentGrantsAmt |
| All Other Contributions | $56,677,575 | AllOtherContributionsAmt |
| Noncash Contributions | $1,358,361 | NoncashContributionsAmt |
| Total Contributions | $81,695,780 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt | Unrelated Business RevenueUnrelatedBusinessRevenueAmt |
|---|---|---|---|---|
| RESEARCH SEQUENCING | 541700 | $5,649,337 | $4,015,225 | $1,634,112 |
| CLINICAL SEQUENCING | 541700 | $4,063,197 | $4,063,197 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $9,712,534 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $191,646 | TotalRevenueColumnAmt |
| Exclusion | $191,646 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,575,796 | TotalRevenueColumnAmt |
| Exclusion | $1,575,796 | ExclusionAmt |
Gross Rents GrossRentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $4,415,161 | RealAmt |
Less Rental Expenses LessRentalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $5,289,599 | RealAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | -$874,438 | RealAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$874,438 | TotalRevenueColumnAmt |
| Exclusion | -$874,438 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | ExclusionExclusionAmt |
|---|---|---|---|
| EDC LOAN RECOGNITION | 900099 | $625,717 | $625,717 |
| OTHER REVENUE | 900099 | $13,394 | $13,394 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $639,111 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $92,940,429 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $8,078,422 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $1,634,112 | UnrelatedBusinessRevenueAmt |
| Exclusion | $1,532,115 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,313,149 | TotalAmt |
| Program Services | $3,313,149 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $74,437 | TotalAmt |
| Program Services | $74,437 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,369,319 | TotalAmt |
| Program Services | $1,971,720 | ProgramServicesAmt |
| Management And General | $1,795,929 | ManagementAndGeneralAmt |
| Fundraising | $601,670 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $22,665,670 | TotalAmt |
| Program Services | $17,476,751 | ProgramServicesAmt |
| Management And General | $4,796,175 | ManagementAndGeneralAmt |
| Fundraising | $392,744 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,411,785 | TotalAmt |
| Program Services | $1,036,439 | ProgramServicesAmt |
| Management And General | $330,002 | ManagementAndGeneralAmt |
| Fundraising | $45,344 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,705,425 | TotalAmt |
| Program Services | $2,105,993 | ProgramServicesAmt |
| Management And General | $563,114 | ManagementAndGeneralAmt |
| Fundraising | $36,318 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,537,993 | TotalAmt |
| Program Services | $1,914,195 | ProgramServicesAmt |
| Management And General | $561,994 | ManagementAndGeneralAmt |
| Fundraising | $61,804 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $270,206 | TotalAmt |
| Management And General | $270,206 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $115,500 | TotalAmt |
| Management And General | $115,500 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $60,069 | TotalAmt |
| Management And General | $60,069 | ManagementAndGeneralAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $14,225 | TotalAmt |
| Fundraising | $14,225 | FundraisingAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,317,557 | TotalAmt |
| Program Services | $3,009,860 | ProgramServicesAmt |
| Management And General | $307,697 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $447,519 | TotalAmt |
| Program Services | $229,260 | ProgramServicesAmt |
| Management And General | $208,452 | ManagementAndGeneralAmt |
| Fundraising | $9,807 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,335,668 | TotalAmt |
| Program Services | $2,083,854 | ProgramServicesAmt |
| Management And General | $1,251,706 | ManagementAndGeneralAmt |
| Fundraising | $108 | FundraisingAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $522,753 | TotalAmt |
| Program Services | $522,753 | ProgramServicesAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $13,279,549 | TotalAmt |
| Program Services | $11,106,579 | ProgramServicesAmt |
| Management And General | $2,066,932 | ManagementAndGeneralAmt |
| Fundraising | $106,038 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $423,273 | TotalAmt |
| Program Services | $356,909 | ProgramServicesAmt |
| Management And General | $64,021 | ManagementAndGeneralAmt |
| Fundraising | $2,343 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $167,798 | TotalAmt |
| Program Services | $101,656 | ProgramServicesAmt |
| Management And General | $44,581 | ManagementAndGeneralAmt |
| Fundraising | $21,561 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $310,369 | TotalAmt |
| Program Services | $193,734 | ProgramServicesAmt |
| Management And General | $114,552 | ManagementAndGeneralAmt |
| Fundraising | $2,083 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,919,358 | TotalAmt |
| Program Services | $4,161,023 | ProgramServicesAmt |
| Management And General | $1,719,870 | ManagementAndGeneralAmt |
| Fundraising | $38,465 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $752,067 | TotalAmt |
| Management And General | $752,067 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (3 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|
| DIRECT COST OF SEQUENCI | $13,033,945 | $13,030,320 | $3,625 |
| RESEARCH | $2,529,791 | $2,529,791 | |
| RECRUITMENT | $46,960 | $16,238 | $30,722 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $248,439 | TotalAmt |
| Program Services | $119,898 | ProgramServicesAmt |
| Management And General | $105,142 | ManagementAndGeneralAmt |
| Fundraising | $23,399 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $81,872,824 | TotalAmt |
| Program Services | $65,354,559 | ProgramServicesAmt |
| Management And General | $15,162,356 | ManagementAndGeneralAmt |
| Fundraising | $1,355,909 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $15,599,937 | BOYAmt |
| EOY | $9,326,778 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| EOY | $3,505,459 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,022,270 | BOYAmt |
| EOY | $18,649,498 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,451,902 | BOYAmt |
| EOY | $7,382,860 | EOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,260,088 | BOYAmt |
| EOY | $1,607,153 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,583,624 | BOYAmt |
| EOY | $2,491,274 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $142,750,837 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $96,679,560 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $43,861,055 | BOYAmt |
| EOY | $46,071,277 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $102,961,575 | BOYAmt |
| EOY | $95,017,931 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $181,740,451 | BOYAmt |
| EOY | $184,052,230 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,934,093 | BOYAmt |
| EOY | $7,098,614 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $15,840,681 | BOYAmt |
| EOY | $14,803,697 | EOYAmt |
Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,380,000 | BOYAmt |
| EOY | $2,660,000 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $119,737,208 | BOYAmt |
| EOY | $113,573,845 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $146,891,982 | BOYAmt |
| EOY | $138,136,156 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $22,710,365 | BOYAmt |
| EOY | $20,204,925 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,138,104 | BOYAmt |
| EOY | $25,711,149 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $34,848,469 | BOYAmt |
| EOY | $45,916,074 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $181,740,451 | BOYAmt |
| EOY | $184,052,230 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $11,067,605 | ReconcilationRevenueExpnssAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $32,878,926 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $51,639,109 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $61,556,925 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $53,970,524 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $81,695,780 | CurrentTaxYearAmt |
| Total | $281,741,264 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $32,878,926 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $51,639,109 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $61,556,925 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $53,970,524 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $81,695,780 | CurrentTaxYearAmt |
| Total | $281,741,264 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $97,345,673 | SubstantialContributorsTotAmt |
| Public Support Total170 | $184,395,591 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $3,205,975 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $3,312,682 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $4,952,174 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $5,045,294 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $6,808,320 | CurrentTaxYearAmt |
| Total | $23,324,445 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $38,049 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $742,082 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $258,491 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $19,731 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $13,394 | CurrentTaxYearAmt |
| Total | $1,071,747 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $306,137,456 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $47,893,123 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.60230 | PublicSupportCY170Pct |
| Public Support PY170 | 0.51100 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | 0 | VolunteersInd |
| Paid Staff Or Management | Yes (1) | PaidStaffOrManagementInd |
| Media Advertisements | 0 | MediaAdvertisementsInd |
| Mailings Members | 0 | MailingsMembersInd |
| Publications Or Broadcast | 0 | PublicationsOrBroadcastInd |
| Grants Other Organizations | 0 | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | 0 | DirectContactLegislatorsInd |
| Rallies Demonstrations | 0 | RalliesDemonstrationsInd |
| Other Activities | Yes (1) | OtherActivitiesInd |
| Other Activities | $70,695 | OtherActivitiesAmt |
| Total Lobbying Expenditures | $70,695 | TotalLobbyingExpendituresAmt |
| Not Described Section501c3 | 0 | NotDescribedSection501c3Ind |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II-B, LINE 1: | FormAndLineReferenceDesc |
| Explanation | THROUGH ITS LEGISLATIVE CONSULTANTS, NYGC ADVOCATES FOR GOVERNMENT FUNDS TO SUPPORT CURRENT OPERATIONS AND/OR EXPAND RESEARCH OPPORTUNITIES AT NYGC. IN 2023, NYGC ENGAGED PAID LEGISLATIVE CONSULTANTS TO REPRESENT ITS INTERESTS AT THE STATE LEVEL. ADDITONALLY, FROM TIME TO TIME, NYGC STAFF MAY CONTACT MEMBERS OF THE STATE LEGISLATURE AND EXECUTIVE BRANCH TO ENCOURAGE THEIR SUPPORT FOR NYGC. SUCH CONTACT MAY INCLUDE MEETINGS AND CORRESPONDENCE WITH PUBLIC OFFICIALS. THE APPROXIMATE COST ASSOCIATED WITH THESE ACTIVITIES IN 2023 WAS $9,003.94. NYGC ALSO MAINTAINS MEMBERSHIPS IN IRC SECTION 501(C)(6) ORGANIZATIONS THAT REPRESENT THE INTERESTS OF THE ACADEMIC MEDICAL RESEARCH COMMUNITY. IN 2023, $2,433 OF THE DUES PAID TO THESE ASSOCIATIONS WERE ATTRIBUTABLE TO LOBBYING. | ExplanationTxt |
Schedule D IRS990ScheduleD
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $0 | BeginningYearBalanceAmt |
| Contributions | $3,481,000 | ContributionsAmt |
| End Year Balance | $3,481,000 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 1.00000 | BoardDesignatedBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | 0 | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $74,702,817 | OtherCostOrOtherBasisAmt |
| Depreciation | $34,209,789 | DepreciationAmt |
| Book Value | $40,493,028 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $64,620,148 | OtherCostOrOtherBasisAmt |
| Depreciation | $59,227,023 | DepreciationAmt |
| Book Value | $5,393,125 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $3,427,872 | OtherCostOrOtherBasisAmt |
| Depreciation | $3,242,748 | DepreciationAmt |
| Book Value | $185,124 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $46,071,277 | TotalBookValueLandBuildingsAmt |
Other Assets Org OtherAssetsOrgGrp (3 entries)
| DescDesc | Book ValueBookValueAmt |
|---|---|
| SECURITY DEPOSITS | $5,516,257 |
| DEFERRED COMPENSATION | $301,841 |
| OPERATING RIGHT OF USE ASSET | $89,199,833 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Other Assets | $95,017,931 | TotalBookValueOtherAssetsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)
| DescDesc | AmtAmt |
|---|---|
| RIGHT OF USE LIABILITY | $111,520,594 |
| FINANCE LEASE OBLIGATIONS | $2,053,251 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $113,573,845 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $98,230,028 | TotalRevEtcAuditedFinclStmtAmt |
| Revenue Not Reported | $0 | RevenueNotReportedAmt |
| Revenue Subtotal | $98,230,028 | RevenueSubtotalAmt |
| Other Revenues Not Included | -$5,289,599 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | -$5,289,599 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $92,940,429 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $87,162,423 | TotExpnsEtcAuditedFinclStmtAmt |
| Other Expenses Included | $5,289,599 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $5,289,599 | ExpensesNotReportedAmt |
| Expenses Subtotal | $81,872,824 | ExpensesSubtotalAmt |
| Expenses Not Rpt Fincl Stmt | $0 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $81,872,824 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (4 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART V, LINE 4: | THE THOMAS MANIATIS CHAIR FOR EXCELLENCE AND INNOVATION IN GENOMIC SCIENCE FUND WAS ESTABLISHED TO RECOGNIZE AND HONOR THE INTEGRAL ROLE PLAYED BY THOMAS MANIATIS, PH.D., IN MAKING THE NEW YORK GENOME CENTER A LEADER IN THE FURTHERANCE OF GENOMIC RESEARCH. A DESIGNATED PORTION, APPROXIMATELY 5% OF THE FUND'S EARNINGS ANNUALLY WILL BE MADE AVAILABLE FOR GENERAL EXPENDITURE. THE BOARD OF DIRECTORS HAS DISCRETION TO MAKE ADDITIONAL FUNDS AVAILABLE TO SUPPORT THE ESSENTIAL NEEDS OF THE ORGANIZATION. |
| PART X, LINE 2: | NYGC IS SUBJECT TO THE PROVISIONS OF THE FASB ASC SECTION 740-10-05, INCOME TAXES - OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. NYGC RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2023 AND 2022. |
| PART XI, LINE 4B - OTHER ADJUSTMENTS: | RECLASS OF DIRECT RENTAL EXPENSE -5,289,599. |
| PART XII, LINE 2D - OTHER ADJUSTMENTS: | RECLASS OF DIRECT RENTAL EXPENSE 5,289,599. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | 0 | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (3 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND AND GREENLAND) | 0 | 9 | PROGRAM SERVICES | RESEARCH | $477,168 |
| NORTH AMERICA | 0 | 3 | PROGRAM SERVICES | RESEARCH | $252,589 |
| EAST ASIA AND THE PACIFIC | 0 | 1 | PROGRAM SERVICES | RESEARCH | $538 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 13 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 13 | TotalEmployeeCnt |
| Subtotal Spent | $730,295 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $730,295 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (3 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Non Cash AssistanceNonCashAssistanceAmt |
|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND AND GREENLAND) | RESEARCH SUBAWARD | $45,219 | WIRE | $0 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | RESEARCH SUBAWARD | $29,218 | WIRE | $0 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | RESEARCH SUBAWARD | $7,500 | WIRE | $0 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 3 | Total501c3OrgCnt |
Foreign Individuals Grants ForeignIndividualsGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Type Of Assistance | RESEARCH | TypeOfAssistanceTxt |
| Region | NORTH AMERICA | RegionTxt |
| Recipient | 2 | RecipientCnt |
| Cash Grant | $251,450 | CashGrantAmt |
| Manner Of Cash Disbursement | WIRE | MannerOfCashDisbursementTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. |
| PART I, LINE 3: | THE PROGRAM EXPENDITURES ARE REPORTED ON THE ACCRUAL METHOD. |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (14 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|---|
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131ST STREET MC841 | NEW YORK | NY | 100277922 | 135598093 | 501(C)(3) | $503,374 | $0 | RESEARCH SUBAWARD |
| NEW YORK UNIVERSITY | ||||||||
| 70 WASHINGTON SQUARE SOUTH | NEW YORK | NY | 10012 | 135562308 | 501(C)(3) | $371,367 | $0 | RESEARCH SUBAWARD |
| ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE | NEW YORK | NY | 10065 | 131624158 | 501(C)(3) | $319,946 | $0 | RESEARCH SUBAWARD |
| BROWN UNIVERSITY | ||||||||
| 164 ANGELL STREET BOX 1877 | PROVIDENCE | RI | 02912 | 050258809 | 501(C)(3) | $285,507 | $0 | RESEARCH SUBAWARD |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | ||||||||
| 1 GUSTAVE L LEVY PLACE | NEW YORK | NY | 10029 | 136171197 | 501(C)(3) | $274,185 | $0 | RESEARCH SUBAWARD |
| NYU GROSSMAN SCHOOL OF MEDICINE | ||||||||
| 550 FIRST AVENUE | NEW YORK | NY | 10016 | 135562309 | 501(C)(3) | $251,210 | $0 | RESEARCH SUBAWARD |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 501(C)(3) | $240,597 | $0 | RESEARCH SUBAWARD |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| 3400 N CHARLES STREET | BALTIMORE | MD | 21218 | 520595110 | 501(C)(3) | $197,999 | $0 | RESEARCH SUBAWARD |
| COLD SPRING HARBOR LABORATORY | ||||||||
| 1 BUNGTOWN ROAD | COLD SPRING HARBOR | NY | 11724 | 112013303 | 501(C)(3) | $180,000 | $0 | RESEARCH SUBAWARD |
| YALE UNIVERSITY | ||||||||
| 135 COLLEGE STREET | NEW HAVEN | CT | 06510 | 060646973 | 501(C)(3) | $179,913 | $0 | RESEARCH SUBAWARD |
| MOREHOUSE SCHOOL OF MEDICINE INC | ||||||||
| 720 WESTVIEW DRIVE SW | ATLANTA | GA | 303101458 | 581438873 | 501(C)(3) | $95,049 | $0 | RESEARCH SUBAWARD |
| THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | ||||||||
| 350 COMMUNITY DRIVE | MANHASSET | NY | 11030 | 112673595 | 501(C)(3) | $77,917 | $0 | RESEARCH SUBAWARD |
| WEILL CORNELL MEDICAL COLLEGE | ||||||||
| 1300 YORK AVENUE | NEW YORK | NY | 10065 | 150532082 | 501(C)(3) | $66,197 | $0 | RESEARCH SUBAWARD |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | ||||||||
| 1111 FRANKLIN STREET | OAKLAND | CA | 94607 | 943067788 | 501(C)(3) | $28,418 | $0 | RESEARCH SUBAWARD |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 14 | Total501c3OrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TOM MANIATIS PHD | ||||||||||||||
| SCIENTIFIC DIRECTOR & CEO | $659,380 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $659,380 | $0 | $0 | $0 |
| SARAH LESSER AVINS | ||||||||||||||
| SVP, ADVANCEMENT & CHIEF D | $564,596 | $0 | $0 | $0 | $0 | $0 | $19,800 | $0 | $17,274 | $0 | $601,670 | $0 | $0 | $0 |
| ELIZABETH BROOKS O'BRIEN | ||||||||||||||
| VP & GENERAL COUNSEL | $466,101 | $0 | $0 | $0 | $0 | $0 | $19,800 | $0 | $25,008 | $0 | $510,909 | $0 | $0 | $0 |
| SOREN GERMER | ||||||||||||||
| SVP, GENOME TECHNOLOGIES | $437,568 | $0 | $0 | $0 | $0 | $0 | $19,800 | $0 | $17,646 | $0 | $475,014 | $0 | $0 | $0 |
| CAROL ASHE | ||||||||||||||
| CHIEF BUSINESS OFFICER | $436,587 | $0 | $0 | $0 | $0 | $0 | $19,800 | $0 | $117 | $0 | $456,504 | $0 | $0 | $0 |
| THOMAS LEHNER | ||||||||||||||
| SCI DIR, NEURO DIS GEN | $404,554 | $0 | $0 | $0 | $0 | $0 | $19,800 | $0 | $13,960 | $0 | $438,314 | $0 | $0 | $0 |
| MARIA JOANTA | ||||||||||||||
| CHIEF FINANCIAL OFFICER | $385,336 | $0 | $0 | $0 | $0 | $0 | $19,800 | $0 | $30,138 | $0 | $435,274 | $0 | $0 | $0 |
| MICHAEL CHARLES ZODY | ||||||||||||||
| SCIENTIFIC DIR, COMP BIOLO | $369,902 | $0 | $0 | $0 | $0 | $0 | $19,800 | $0 | $9,310 | $0 | $399,012 | $0 | $0 | $0 |
| CHARLES GAGNON | ||||||||||||||
| CHIEF INFORMATION OFFICER | $339,799 | $0 | $0 | $0 | $4,313 | $0 | $17,504 | $0 | $31,627 | $0 | $393,243 | $0 | $0 | $0 |
| SHAILAJA GARGEYA | ||||||||||||||
| SENIOR DIR, SOFTWARE ENGIN | $322,162 | $0 | $10,470 | $0 | $56 | $0 | $19,800 | $0 | $117 | $0 | $352,605 | $0 | $0 | $0 |
| DAYNA M OSCHWALD | ||||||||||||||
| CHIEF OF STAFF | $282,420 | $0 | $0 | $0 | $56 | $0 | $16,917 | $0 | $17,055 | $0 | $316,448 | $0 | $0 | $0 |
| CHRISTOPHER PHIFER BLACK | ||||||||||||||
| SENIOR DIRECTOR, RESEARCH | $255,308 | $0 | $0 | $0 | $0 | $0 | $15,753 | $0 | $28,578 | $0 | $299,639 | $0 | $0 | $0 |
| CATHERINE E REEVES | ||||||||||||||
| SENIOR DIRECTOR, RESEARCH | $238,710 | $0 | $4,500 | $0 | $0 | $0 | $15,150 | $0 | $17,646 | $0 | $276,006 | $0 | $0 | $0 |
| HANNAH GOULDING | ||||||||||||||
| SENIOR DIRECTOR, HUMAN RES | $245,119 | $0 | $0 | $0 | $0 | $0 | $14,707 | $0 | $117 | $0 | $259,943 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 3 | FormAndLineReferenceDesc |
| Explanation | IN 2023, NYGC'S SCIENTIFIC DIRECTOR & CEO WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR & CEO, AN OFFICER OF THE CORPORATION AND AS A SENIOR ASSOCIATE MEMBER OF NYGC'S FACULTY. HE OVERSAW NYGC'S RESEARCH PROGRAM AND UNDERTOOK OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTED 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. IN 2023, NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION, INCLUDING THE SCIENTIFIC DIRECTOR & CEO. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT, INCLUDING THE SCIENTIFIC DIRECTOR & CEO, WAS REASONABLE. | ExplanationTxt |
Schedule L IRS990ScheduleL
Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp
Name Of Interested NameOfInterested
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | SILAS MANIATIS | PersonNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Relationship Description | FAMILY MEMBER | RelationshipDescriptionTxt |
| Transaction | $180,439 | TransactionAmt |
| Transaction | SALARY+BENEFITS | TransactionDesc |
| Sharing Of Revenues | 0 | SharingOfRevenuesInd |
Schedule M IRS990ScheduleM
Other Non Cash Contri Table OtherNonCashContriTableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Desc | RESEARCH SUPPLIES | Desc |
| Contribution | 103 | ContributionCnt |
| Noncash Contributions Rpt F990 | $1,358,361 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | 0 | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (13 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART I, LINE 1 & PART III, LINE 1: | THE NEW YORK GENOME CENTER (NYGC) IS AN INDEPENDENT NON-PROFIT SCIENTIFIC RESEARCH INSTITUTION DEDICATED TO COLLABORATIVE GENETIC AND GENOMIC RESEARCH. NYGC'S MISSION IS TO ADVANCE GENOMIC SCIENCE, AND THROUGH ITS APPLICATION, TO DRIVE NOVEL BIOMEDICAL DISCOVERIES. NYGC'S AREAS OF FOCUS INCLUDE THE DEVELOPMENT OF COMPUTATIONAL AND EXPERIMENTAL GENOMIC METHODS AND DISEASE-FOCUSED RESEARCH TO BETTER UNDERSTAND THE GENETIC BASIS OF CANCER, NEURODEGENERATIVE DISEASE AND NEUROPSYCHIATRIC DISEASE. THE NYGC TEAM, LED BY EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO TOM MANIATIS, PHD, INCLUDES ASSOCIATE AND CORE FACULTY MEMBERS WHO HOLD JOINT APPOINTMENTS AT LEADING ACADEMIC INSTITUTIONS. THE CENTER BRINGS TOGETHER OUTSTANDING THOUGHT LEADERS FROM TEN FOUNDING & THREE ASSOCIATE MEMBER INSTITUTIONS, AND 96 AFFILIATE SCIENTIFIC MEMBERS TO ENGAGE IN COLLABORATIVE RESEARCH. CONVENING TALENT AND EXPERTISE FROM MULTIPLE TOP-TIER SCIENTIFIC AND MEDICAL INSTITUTIONS IN THE NEW YORK AREA AND BEYOND, WE HAVE CREATED A HIGHLY COLLABORATIVE SCIENTIFIC ECOSYSTEM AND COMMUNITY RESOURCE THAT IS MORE THAN THE SUM OF ITS PARTS. NYGC ALSO PROVIDES RESEARCHERS WITH ACCESS TO STATE-OF-THE-ART GENOMIC INFRASTRUCTURE (E.G., COMPUTER HARDWARE AND SOFTWARE, SEQUENCING INSTRUMENTS) AND TECHNOLOGY INNOVATION AND EXPERTISE. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) LEADING AND CONTRIBUTING TO INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY, ACROSS THE COUNTRY AND AROUND THE WORLD. (II) RECRUITING AND RETAINING DIVERSE WORLD-CLASS SCIENTIFIC TALENT TO LEAD THE ORGANIZATION'S RESEARCH AND TECHNOLOGY DEVELOPMENT PROGRAMS; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO ADVANCE NYGC'S SCIENTIFIC RESEARCH MISSION; (IV) DEVELOPING INNOVATIVE EXPERIMENTAL AND COMPUTATIONAL GENOMIC METHODS BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE ORGANIZATION'S FACILITY, FOR THE BROADER BENEFIT OF THE RESEARCH COMMUNITY; (V) IMPROVING HUMAN HEALTH THROUGH GENOMIC RESEARCH THAT DRIVES NOVEL BIOMEDICAL DISCOVERIES; (VI) STRIVING TO MAXIMIZE THE BENEFITS OF OUR RESEARCH AND INNOVATION FOR DIVERSE COMMUNITIES; (VII) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH AND TECHNOLOGY COMMUNITIES; (VIII) CREATING A WORKPLACE ENVIRONMENT THAT IS WELCOMING AND FAIR TO ALL REGARDLESS OF RACE, ETHNICITY, GENDER, SEXUAL ORIENTATION, PHYSICAL DISABILITY, AGE, OR RELIGION, AND (IX) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES. NYGC STRIVES TO CHAMPION DIVERSITY, EQUITY, AND INCLUSION IN ITS WORKPLACE AND IN THE APPLICATION OF ITS RESEARCH TO CLINICAL CARE. A FUNDAMENTAL GOAL OF THE GENOME CENTER IS ADDRESSING THE LACK OF DIVERSITY WITHIN DATA, SAMPLES, AND SUBJECTS IN GENOMICS RESEARCH. NYGC IS ALSO COMMITTED TO DIVERSITY ON THE CENTER'S BOARD OF DIRECTORS AND WITHIN ITS FACULTY, STAFF, AND SCIENTIFIC RESEARCHERS. |
| FORM 990, PART III, LINE 4A & LINE 4B | NEUROPSYCHIATRIC DISEASE: THE NEW YORK GENOME CENTER IS BUILDING A NEUROPSYCHIATRIC DISEASE RESEARCH PROGRAM AIMED AT INVESTIGATING THE MECHANISMS UNDERLYING NEUROPSYCHIATRIC AND NEURODEVELOPMENTAL DISORDERS, SUCH AS SCHIZOPHRENIA, BIPOLAR DISORDER, AND AUTISM SPECTRUM DISORDER. NYGC'S VISION ENCOMPASSES A MULTI-LAYERED APPROACH, INTEGRATING VARIOUS LEVELS OF ANALYSIS TO ADVANCE OUR UNDERSTANDING OF THE BIOLOGICAL UNDERPINNINGS OF NEUROPSYCHIATRIC DISORDERS. THIS INCLUDES DELINEATING THE GENETIC AND PHENOTYPIC ARCHITECTURE OF THESE DISORDERS IN DIVERSE POPULATIONS AND PERFORMING FUNCTIONAL STUDIES TO UNRAVEL THEIR UNDERLYING BIOLOGY, USING DIVERSE MODEL SYSTEMS. NYGC IN PARTNERSHIP WITH INSTITUTIONAL FOUNDING MEMBERS WILL BUILD A TRANSLATIONAL PLATFORM FOR PRECISION PSYCHIATRY DEDICATED TO PROVIDING PATIENTS WITH ACCESS TO EVIDENCE-BASED MENTAL HEALTH CARE, WITH SPECIAL EMPHASIS ON DATA SECURITY AND PATIENT PRIVACY. AN NYGC SIGNATURE PROJECT IN NEUROPSYCHIATRIC DISEASE RESEARCH IS THE GENOMIC MEDICINE FOR MENTAL HEALTH ADVANCEMENT (GEMMA) INITIATIVE, WHICH AIMS TO DEVELOP A PATIENT-CENTRIC PLATFORM FOR PRECISION PSYCHIATRY. GEMMA , A COLLABORATION BETWEEN THE NYGC, COLUMBIA UNIVERSITY, NORTHWELL HEALTH, AND THE NEW YORK STATE OFFICE OF MENTAL HEALTH WILL BE DEDICATED TO PROVIDING PATIENTS WITH ACCESS TO EVIDENCE BASED MENTAL HEALTH CARE AND THE INTEGRATION OF GENETIC AND CLINICAL RECORDS INTO PROGNOSIS, AND CLINICAL CARE. THE PLATFORM"S INITIAL TARGET POPULATION ARE THE HISTORICALLY UNDERSERVED POPULATIONS OF THE NEW YORK STATE MENTAL HEALTH SYSTEM. BEGINNING IN 2023, NYGC TOGETHER WITH THE BROAD INSTITUTE OF MIT AND HARVARD, AND THE UNIVERSITY OF CALIFORNIA, LOS ANGELES, WILL COLLABORATE TO CREATE THE BD GENETICS PLATFORM. THIS PLATFORM WILL BE USED TO PERFORM GENOMIC PROFILING OF ONE OF THE MOST DIVERSE POPULATIONS OF PEOPLE WITH BIPOLAR DISORDER, INCLUDING MORE THAN 30,000 STUDY SUBJECTS FROM AFRICA, CENTRAL AMERICA, SOUTH AMERICA, AND ASIA. ADDITIONALLY, NYGC IS ADVANCING ITS CLINICAL OUTCOME PREDICTION OF PSYCHOSIS FROM ELECTRONIC HEALTH RECORDS (COPPER), A PILOT STUDY LEVERAGING THE GEMMA PLATFORM FOCUSED ON ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING, TO BUILD MODELS OF CLINICAL PREDICTORS OF DIAGNOSIS, TREATMENT, AND PROGNOSIS OF PSYCHOSIS-RELATED DISORDERS. IN PRECISION PSYCHIATRY, THE NYGC TEAM PLANS TO INTEGRATE LARGE-SCALE LONGITUDINAL ELECTRONIC HEALTH RECORDS, DIMENSIONAL PHENOTYPING, AND GENETIC ANALYSES TO IMPROVE CLINICAL PREDICTORS OF SERIOUS MENTAL ILLNESS. BEGINNING IN 2023, DR. LEHNER AND ASSOCIATE FACULTY MEMBER, DR. TARJINDER SINGH, LAUNCHED A NEW PROJECT TO CARRY OUT WHOLE GENOME SEQUENCING AND BIOINFORMATIC ANALYSIS ON A WELL-CHARACTERIZED COHORT OF PATIENTS WITH SEVERE SCHIZOPHRENIA. IN COLLABORATION WITH DR. CARLOS PATO AT RUTGERS UNIVERSITY AND LEVERAGING NEW REDUCED-COST SEQUENCING PLATFORMS, NYGC WILL SEQUENCE AND ANALYZE A COHORT OF 2,500 PATIENTS WITH SEVERE SCHIZOPHRENIA FROM THE RUTGERS GENOMIC PSYCHIATRY COHORT TO IDENTIFY POTENTIALLY CAUSATIVE GENETIC VARIANTS. RESEARCHERS WILL ALSO BE ABLE TO USE CELL LINES DERIVED FROM EACH PARTICIPANT IN THE COHORT TO INVESTIGATE THE UNDERLYING CAUSATIVE DISEASE MECHANISMS. THE RESEARCH TEAM PLANS TO INTEGRATE THE WHOLE GENOME SEQUENCE DATA WITH EXISTING LARGE-SCALE DATASETS, CONTROLS, AND INTERNATIONAL DISCOVERY EFFORTS TO ADVANCE PRECISION MEDICINE IN PSYCHIATRY. GENOMIC TECHNOLOGY: NYGC'S TECHNOLOGY INNOVATION LAB HAS POSITIONED THE CENTER AT THE LEADING EDGE OF GENOMIC TECHNOLOGY INNOVATION, ALLOWING FOR DEEPER FUNCTIONAL STUDIES OF DISEASE BIOLOGY WITH INCREASING RESOLUTION AND BROADER ACCESSIBILITY FOR THE RESEARCH COMMUNITY. THESE INCLUDE THE DEVELOPMENT OF HIGH-THROUGHPUT TECHNOLOGIES FOR SIMULTANEOUS MEASUREMENT OF PROTEINS, RNA, AND CHROMATIN STRUCTURE AT SPATIAL RESOLUTIONS AT OR BELOW THE SINGLE CELL LEVEL, ALONG WITH SOPHISTICATED COMPUTATIONAL AND STATISTICAL TOOLS TO FURTHER THE ANALYSIS OF MULTI-MODAL GENOMICS. THE TECHNOLOGY INNOVATION LAB IS ACTIVELY INVOLVED IN ADVANCING SPATIALLY-RESOLVED SINGLE CELL TECHNOLOGIES, WHICH CAN SIMULTANEOUSLY MAP THE ACTIVITIES OF TENS OF THOUSANDS OF GENES ACROSS TISSUE SECTIONS. THE LAB PLAYED A PIVOTAL ROLE IN THE INVENTION OF SPATIAL TRANSCRIPTOMICS (ST), A GROUNDBREAKING METHOD THAT WAS NAMED METHOD OF THE YEAR IN 2020, EMPOWERING RESEARCHERS TO UNRAVEL THE COMPLEXITIES OF DISEASE GENERATION WITH UNPRECEDENTED RESOLUTION. THIS YEAR, THE TECHNOLOGY INNOVATION LAB HAS BEEN WORKING TO PUSH THE BOUNDARIES OF CURRENT ST TECHNIQUES TO ADVANCE THE TECHNOLOGY AND ITS APPLICATION. AS A RESULT, THE LAB HAS PIONEERED A NOVEL ST TECHNOLOGY EMPLOYING SIMPLE MICROFLUIDICS AND 3D PRINTABLE TOOLING TO CREATE GLASS SLIDES WITH SPATIALLY BARCODED REGIONS FOR INCREASED SPATIAL RESOLUTION, CONTINUOUS AND EFFICIENT CAPTURING, AND A LARGE FIELD OF VIEW, BROADENING THE UTILITY AND APPLICATIONS OF ST. THIS NEW METHOD MAINTAINS COST-EFFECTIVENESS AND ALLOWS FOR EASY CUSTOMIZATION ENABLING BROADER ADOPTION WITHIN THE SCIENTIFIC COMMUNITY. IN GENOMICS RESEARCH, THERE HAS ALSO BEEN A SIGNIFICANT BREAKTHROUGH AND INCREASED FOCUS ON OPTICAL MULTI-OMICS (OMO) TECHNOLOGIES THAT CAN MEASURE THE ACTIVITY OR ABUNDANCE OF RNA AND PROTEIN SIMULTANEOUSLY AND AT SINGLE-CELL RESOLUTION WITHIN INTACT TISSUES. THE TECHNOLOGY INNOVATION LAB HAS DEVELOPED AN OPEN-SOURCE CODE BASE AND CONSUMABLE DESIGN SET, TO REPURPOSE RETIRED HIGH-END DNA SEQUENCERS INTO OMO HARDWARE THAT IS EQUIVALENT TO COMMERCIAL PLATFORMS. THIS INNOVATIVE AND COST-EFFECTIVE SOLUTION ALLOWS RESEARCHERS TO GO FROM TISSUE TO ANALYZED DATA IN A MATTER OF DAYS OR EVEN HOURS, OVERCOMING FINANCIAL AND LEGAL CONSTRAINTS ASSOCIATED WITH COMMERCIAL OMO SOLUTIONS. THE TECHNOLOGY INNOVATION LAB HAS BEEN WORKING TO DEVELOP COMPANION COMPUTATIONAL APPROACHES ENABLING SPATIAL MODELING OF SUCH HIGHLY COMPLEX DATA ACROSS LARGE COHORTS OF TISSUE SAMPLES AND INDIVIDUALS, PROVIDING A COMPREHENSIVE UNDERSTANDING OF THE IMPACT OF DISEASE AND AGING ON VARIOUS ORGANS, FROM THE BRAIN TO THE LARGE INTESTINE. |
| FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED) | CLINICAL LABORATORY: NYGC'S CLINICAL LABORATORY CONTINUES TO LEVERAGE ITS INFRASTRUCTURE AND EXPERTISE FOR SEVERAL LARGE-SCALE INITIATIVES IN CLINICAL GENOMICS, INCLUDING A COLLABORATION WITH WEILL CORNELL MEDICINE, NEWYORK-PRESBYTERIAN HOSPITAL ON A PRECISION MEDICINE INITIATIVE FOCUSED ON CANCER, CARDIOLOGY, ENDOCRINOLOGY, AND NEUROLOGY. THE AIM IS TO ENHANCE THE VALUE OF CLINICAL WHOLE GENOMES, RETURN CLINICALLY ACTIONABLE RESULTS, AND GAIN A DEEPER UNDERSTANDING OF THE ROLE OF GENETICS IN THERAPEUTIC RESPONSES. THE FINDINGS FROM THESE EFFORTS HAVE BEEN PRESENTED AT THE ACMG MEETING, AND NYGC PLANS TO CONTINUE UPDATING ITS PANELS TO INCORPORATE NEW GENETIC INSIGHTS ANNUALLY. THE CLINICAL LABORATORY HAS INITIATED A COLLABORATION WITH THE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY AT COLUMBIA UNIVERSITY, ESTABLISHING THE WOMEN'S GENETICS CENTER (WGC). THIS CENTER LEVERAGES THE COMBINED STRENGTHS OF COLUMBIA'S MATERNAL-FETAL MEDICINE PHYSICIANS AND GENETIC COUNSELORS, ALONG WITH TNYGC'S LEADING EXPERTISE IN TECHNOLOGY AND CLINICAL GENETICS. THE WGC IS DEDICATED TO DEVELOPING AND IMPLEMENTING NOVEL CLINICAL TESTS TO IMPROVE CARE FOR PREGNANT WOMEN. TO DATE, THE CLINICAL LABORATORY HAS PERFORMED OVER 1,200 WHOLE-GENOME SEQUENCING (WGS) PRENATAL TESTS TO IDENTIFY GENETIC CAUSES OF ANOMALIES DETECTED VIA ULTRASOUND IN SUPPORT OF THIS EFFORT. ADDITIONALLY, PLANS ARE UNDERWAY TO DEVELOP MORE INNOVATIVE WHOLE-GENOME-BASED TESTS THAT WILL BENEFIT ROUTINE PRENATAL DIAGNOSIS, INCLUDING FOR NON-ANOMALOUS CASES. THESE EFFORTS AIM TO DEMONSTRATE THE VALUE OF PRENATAL GENETIC SEQUENCING (GS) FOR ANOMALIES, STILLBIRTH, AND ROUTINE PRENATAL DIAGNOSIS. THE WGC AIMS TO ESTABLISH ITSELF AS A NATIONAL AND INTERNATIONAL LEADER IN FETAL GENOMICS AND PRECISION MEDICINE BY BUILDING THE NECESSARY DATA FOR OBTAINING REIMBURSEMENT FOR CLINICAL GS TESTS. FURTHERMORE, THE WGC IS COMMITTED TO DELIVERING INNOVATIVE HEALTHCARE SOLUTIONS TAILORED TO PATIENTS OF DIVERSE RACIAL, ETHNIC, AND SOCIOECONOMIC BACKGROUNDS, ULTIMATELY DEMONSTRATING THE BROAD BENEFITS OF CLINICAL GS TO THE WIDER COMMUNITY. NYGC HAS BEEN CHOSEN AS A CLINICAL SITE FOR THE IHOPE GENETIC HEALTH INITIATIVE, A NEWLY LAUNCHED PRO BONO GENETIC TESTING PROGRAM. THIS INITIATIVE AIMS TO CREATE A GLOBAL NETWORK OF LABORATORIES AND CLINICAL SITES TO PROVIDE GENETIC TESTING FOR UNDIAGNOSED CHILDREN FROM UNDER-RESOURCED COMMUNITIES. NYGC IS ONE OF ONLY THREE SEQUENCING LABS WORLDWIDE, AND THE ONLY ONE IN THE UNITED STATES, SELECTED TO PARTICIPATE IN THE INITIAL PHASE. THANKS TO SUCCESSFUL FUNDRAISING EFFORTS AT NYGC, WE HAVE SECURED SUPPORT TO PROVIDE GENETIC TESTING FOR 85 PATIENTS THROUGH THIS PROGRAM. RESEARCH SEQUENCING: NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST TEN YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 102,800 WHOLE GENOME SAMPLES. NYGC HAS ACQUIRED TWO OF THE NEWEST ILLUMINA NOVASEQ X SYSTEMS SEQUENCERS, EACH WITH THE CAPACITY TO SEQUENCE TWENTY THOUSAND HUMAN GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. IN ADDITION, NYGC OPERATES AN OXFORD NANOPORE PROMETHION SEQUENCER FOR LONG READ SEQUENCING, AND CONTINUED TO TEST AND VALIDATE A HIGH-THROUGHPUT SEQUENCER FROM ULTIMA GENOMICS (THE UG100). NYGC'S RESEARCH SEQUENCING LAB, LED BY SOREN GERMER, PHD, SENIOR VICE PRESIDENT OF GENOME TECHNOLOGIES, PROCESSED MORE THAN 28,000 SAMPLES IN 2023, INCLUDING 4,226 WHOLE GENOME SEQUENCING SAMPLES (GERMLINE AND CANCER), AND 18,182 TRANSCRIPTOME (RNA) SEQUENCING SAMPLES. IN 2023, NYGC CONTINUED TO FOCUS ITS OPERATIONAL EFFORTS ON SINGLE CELL MULTI-OMICS, EXPANDING THE SCOPE OF APPLICATION FOR CUTTING-EDGE TECHNIQUES AVAILABLE TO THE RESEARCH COMMUNITY, INCLUDING CITE-SEQ, ECCITE-SEQ, SINGLE-NUCLEUS RNA-SEQ, DOGMA-SEQ, SINGLE-CELL LONG READ RNA AND ATAC-SEQ AND THE 10X MULTIOME ASSAY, THROUGH FUNCTIONAL GENOMIC COLLABORATIONS ACROSS MULTIPLE TISSUE TYPES AND DISEASES. THESE TECHNIQUES ALLOW SIMULTANEOUS MEASUREMENT IN THOUSANDS OF CELLS COMBINATIONS OF CELL SURFACE PROTEIN MARKERS, T-CELL AND B-CELL ANTIGEN RECEPTORS, RNA ABUNDANCE AND CHROMATIN ACCESSIBILITY INCREASING SCALE THROUGH HASHING WHICH ENABLES SAMPLE MULTIPLEXING. THE CENTER'S TECHNOLOGY DEVELOPMENT LABORATORY HAS COMPLETED SEVERAL PROJECTS IN WHICH THESE ASSAYS HAVE BEEN APPLIED SUPPORTING RESEARCH IN SCHIZOPHRENIA AND ALZHEIMER'S DISEASES FROM INDUCED PLURIPOTENT STEM DIFFERENTIATED CNS CELLS AND BRAIN TISSUE. THE LAB IS ALSO ACTIVELY SUPPORTING MULTIPLE LARGE-SCALE GRANTS INCLUDING SINGLE NUCLEUS TRANSCRIPTOME PROFILING OF POSTMORTEM SPINAL CORD OF AMYOTROPHIC LATERAL SCLEROSIS PATIENTS IN COLLABORATION WITH COLUMBIA UNIVERSITY; MULTI-OMICS MAPS OF HUMAN ENDOMETRIUM IN DIVERSE ANCESTRIES IN COLLABORATION WITH COLD SPRING HARBOR LABORATORY, NORTHWELL HEALTH AND WEILL CORNELL MEDICAL CENTER; AND THE STUDY OF THE INITIATION OF DIFFUSE AND INTESTINAL NON-CARDIA GASTRIC CANCER IN COLLABORATION WITH COLUMBIA UNIVERSITY. IN ADDITION, THE LAB CONTINUES TO SUPPORT A LARGE STUDY OF ESOPHAGEAL CANCER IN COLLABORATION WITH COLUMBIA UNIVERSITY AND CAMBRIDGE UNIVERSITY UTILIZING A NOVEL AMPLIFICATION FREE SINGLE CELL WHOLE GENOME SEQUENCING ASSAY. DIVERSITY, EQUITY, AND INCLUSION: IN 2020, NYGC LAUNCHED AN ORGANIZATION-WIDE DIVERSITY, EQUITY, AND INCLUSION ("DEI") INITIATIVE, AFFIRMING NYGC'S COMMITMENT TO TAKE ACTIONABLE STEPS TOWARD FOSTERING A COMMUNITY ENVIRONMENT THAT IS WELCOMING AND INCLUSIVE TO ALL. EACH EMPLOYEE HAS THE RIGHT TO BE TREATED WITH DIGNITY AND RESPECT OF INDIVIDUAL DIFFERENCES. IN 2023, NYGC'S CROSS-FUNCTIONAL DEI ADVISORY GROUP PROVIDED EDUCATION AND RESOURCES TO THE NYGC COMMUNITY TO RAISE AWARENESS OF DEI AND TO ENHANCE CULTURAL COMPETENCY, SUCH AS BOOK CLUBS, SHOWCASING THE WORK AND SKILLS OF A DIVERSE GROUP OF EMPLOYEES, STAFF, FACULTY AND TRAINEES, AND ORGANIZED DEI-RELATED EVENTS. THE CENTER HIRED A NEW DIRECTOR OF DEI TO SPEARHEAD EXISTING AND EXPANDED DEI EFFORTS. THE DIRECTOR LAUNCHED A DIVERSITY, EQUITY & INCLUSION IMPACT AWARD AND INITIATED PLANNING FOR AN INAUGURAL POST BACCALAUREATE EARLY CAREER DEVELOPMENT TRAINING PROGRAM. |
| FORM 990, PART III, LINE 4A & LINE 4B | THE NEW YORK GENOME CENTER (NYGC) IS COMMITTED TO ADVANCING GENOMIC SCIENCE, AND THROUGH ITS APPLICATION, TO DRIVING THE DEVELOPMENT OF NOVEL BIOMEDICAL THERAPEUTICS FOR CLINICAL CARE. RESEARCH AND FACULTY CENTRAL TO THE SUCCESS OF NYGC IS OUR TALENTED FACULTY WHO POSE FUNDAMENTAL QUESTIONS, DEVELOP NOVEL APPROACHES TO SCIENTIFIC INQUIRY, AND DEEPLY PROBE THE BIOLOGICAL MECHANISMS RELEVANT TO HUMAN HEALTH AND DISEASE. THE GENOMIC EXPERTISE OF OUR WORLD-CLASS SCIENTISTS INCLUDES CANCER, NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISEASE, GENOME EDITING, SINGLE-CELL AND SPATIALLY-RESOLVED MULTIOMICS, HIGH-RESOLUTION IMAGING, 3-DIMENSIONAL GENOME STRUCTURE, FUNCTIONAL GENOMICS, WHOLE GENOME SEQUENCING, BIOINFORMATICS, COMPUTATIONAL BIOLOGY, MACHINE LEARNING, GENOMIC DATA PRIVACY, AND MOLECULAR DIAGNOSTICS. EACH FACULTY MEMBER HAS BUILT A ROBUST RESEARCH PROGRAM AND HOLDS A JOINT TENURE-TRACK APPOINTMENT AT ONE OF OUR PARTNER INSTITUTIONS. NYGC ALSO HAS A DISTINGUISHED GROUP OF SENIOR ASSOCIATE FACULTY AND SCIENTIFIC ADVISORY BOARD (SAB) WHO ARE ESTABLISHED LEADERS IN GENOMICS AND BRING INVALUABLE SCIENTIFIC LEADERSHIP AND MENTORSHIP TO THE CENTER. OUR SENIOR LEADERSHIP TEAM, TOGETHER WITH THE EXTENSIVE EXPERIENCE AND GUIDANCE OF OUR SENIOR FACULTY AND SAB, EMPOWERS THE NEXT GENERATION OF GENOMIC RESEARCHERS TO INNOVATE AND DRIVE BREAKTHROUGHS IN BIOMEDICAL RESEARCH. IN 2023, WE EXPANDED THE EXPERTISE OF OUR ASSOCIATE FACULTY, A STRATEGIC STEP FORWARD. WITH THESE APPOINTMENTS, WE ADDED DEPTH, BREADTH, AND SCOPE TO THE GENOM\E CENTER'S OVERALL RESEARCH PROGRAM. THE NEW MEMBERS INCLUDE: STEPHAN SANDERS, PHD, BMBS, ALSO HOLDS JOINT APPOINTMENTS AS A PROFESSOR OF PEDIATRIC NEUROGENETICS IN THE DEPARTMENT OF PEDIATRICS AT THE UNIVERSITY OF OXFORD AND AS A MEMBER OF THE FACULTY AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. DR. SANDERS' RESEARCH FOCUSES ON USING GENE DISCOVERY, FUNCTIONAL GENOMICS, AND BIOINFORMATICS TO UNDERSTAND THE ETIOLOGY OF NEURODEVELOPMENTAL DISORDERS. IN ADDITION TO THEIR APPOINTMENTS AS ETHNICITY AND CANCER SCHOLARS FOR NYGC'S POLYETHNIC-1000 (P-1000) PROGRAM, ONYINYE BALOGUN, MD AND MELISSA DAVIS, PHD HAVE ACCEPTED ASSOCIATE FACULTY APPOINTMENTS AT THE GENOME CENTER. ONYINYE BALOGUN, MD HOLDS A JOINT APPOINTMENT AS ASSISTANT PROFESSOR OF RADIATION ONCOLOGY AT WEILL CORNELL MEDICINE SPECIALIZING IN THE TREATMENT OF BREAST AND GYNECOLOGIC MALIGNANCIES. DR. BALOGUN HAS CONDUCTED AND PUBLISHED BREAST CANCER RESEARCH IN NOVEL THERAPEUTICS FOR TRIPLE NEGATIVE BREAST CANCER AND BRAIN METASTASES. MELISSA DAVIS, PHD HOLDS JOINT APPOINTMENTS AS DIRECTOR OF THE INSTITUTE OF TRANSLATIONAL GENOMIC MEDICINE AND INTERIM ASSOCIATE PROFESSOR OF MICROBIOLOGY BIOCHEMISTRY AND IMMUNOLOGY AT MOREHOUSE SCHOOL OF MEDICINE (MSM) AND ASSOCIATE ADJUNCT PROFESSOR OF DEVELOPMENT AND CELL BIOLOGY, SCIENTIFIC DIRECTOR, INTERNATIONAL CENTER FOR THE STUDY OF BREAST CANCER SUBTYPES, INTERIM DIRECTOR OF HEALTH EQUITY AT THE ENGLANDER INSTITUTE OF PRECISION MEDICINE AT WEILL CORNELL MEDICINE (WCM). DR. DAVIS' RESEARCH FOCUSES ON IDENTIFYING BIOLOGICAL MECHANISMS OF RACIAL DISPARITIES IN CANCER RISK AND CLINICAL OUTCOMES OF CANCER DIAGNOSES. DR. DAVIS HAS JOINED NYGC'S MACMILLAN CSNCG AS A CO-PI, AND IS WORKING WITH NYGC AND INTERNATIONAL COLLABORATORS TO LEAD A CANCER GRAND CHALLENGES (JOINTLY FUNDED BY CANCER RESEARCH UK AND THE NIH NATIONAL CANCER INSTITUTE) PROJECT TEAM FOR SOCIETAL, ANCESTRY, MOLECULAR AND BIOLOGICAL ANALYSES OF INEQUALITIES (SAMBAI). IN 2023, NYGC SCIENTISTS PUBLISHED 69 STUDIES IN HIGH-IMPACT SCIENTIFIC JOURNALS ESTABLISHING NEW INSIGHTS INTO THE CAUSES AND MECHANISMS OF DISEASE, INNOVATIVE NEW GENOMIC TECHNOLOGIES, AND NOVEL COMPUTATIONAL APPROACHES THAT WE SHARE WIDELY WITH THE SCIENTIFIC COMMUNITY TO HELP ADVANCE PRECISION MEDICINE. AT THE CLOSE OF 2023, TWO CORE FACULTY MEMBERS, RAHUL SATIJA, PHD, AND NEVILLE SANJANA, PHD, WERE NAMED AMONG THE WORLD'S MOST CITED RESEARCHERS ON CLARIVATE ANALYTICS' 2023 HIGHLY CITED RESEARCHERS LIST FOR THE FIFTH CONSECUTIVE YEAR. THIS ANNUAL LIST GATHERS THOSE IN THE FIELD WHO DEMONSTRATED SIGNIFICANT AND BROAD INFLUENCE REFLECTED IN THEIR PUBLICATIONS OF MULTIPLE HIGHLY CITED PAPERS OVER THE LAST DECADE. THE HIGHLY CITED PAPERS RANK IN THE TOP 1% BY CITATION FOR A FIELD OR FIELDS AND PUBLICATION YEAR IN THE WEB OF SCIENCE. IN 2023, NYGC FACULTY AND SCIENTISTS WERE THE RECIPIENTS OF SEVERAL PRESTIGIOUS AND COMPETITIVE GRANTS SUPPORTING VARIOUS ASPECTS OF THE CENTER'S PIONEERING RESEARCH. SELECT AWARDS INCLUDE: THE CENTER FOR NEUROPSYCHIATRIC DISEASE, LED BY DR. THOMAS LEHNER, NYGC'S SCIENTIFIC DIRECTOR FOR NEUROPSYCHIATRIC DISEASE, RECEIVED TWO GRANTS IN SEPARATE ROUNDS OF FUNDING FROM BD: BREAKTHROUGH DISCOVERIES FOR THRIVING WITH BIPOLAR DISORDER. THE FIRST GRANT TOTALING $15M WAS AWARDED TO THE NYGC ALONG WITH THE BROAD INSTITUTE OF MIT AND HARVARD, AND THE UNIVERSITY OF CALIFORNIA, LOS ANGELES (UCLA) TO SUPPORT THE CREATION OF THE BD GENETICS PLATFORM. THIS COLLABORATIVE EFFORT WILL PERFORM GENETIC SEQUENCING ON ONE OF THE LARGEST AND MOST DIVERSE POPULATIONS OF PEOPLE WITH BIPOLAR DISORDER, INCLUDING MORE THAN 30,000 STUDY SUBJECTS FROM AFRICA, CENTRAL AMERICA, SOUTH AMERICA AND ASIA. IN COLLABORATION WITH RUTGERS UNIVERSITY AND COLUMBIA UNIVERSITY, A SECOND GRANT FROM BD WAS ANNOUNCED LATER IN THE YEAR, NAMING NYGC AS A RECIPIENT OF A THREE-YEAR $4.5M GRANT TO SUPPORT RESEARCH AIMED AT FURTHER UNDERSTANDING THE BIOLOGICAL PROCESSES UNDERLYING BIPOLAR DISORDER. THE CENTER'S COMMITMENT TO COLLABORATIVE SCIENCE WAS ALSO RECOGNIZED THROUGH A TWO-YEAR TARGET ALS GRANT AWARDED TO HEMALI PHATNANI, PHD, CORE FACULTY MEMBER AND DIRECTOR OF THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND) AND SANJA VICKOVIC, PHD, CORE FACULTY MEMBER AND DIRECTOR OF THE TECHNOLOGY INNOVATION LAB. THEIR MULTI-YEAR GRANT SUPPORTS THE PROJECT "CREATING A SPATIAL GENOMICS RESOURCE FOR AMYOTROPHIC LATERAL SCLEROSIS-FRONTOTEMPORAL DEMENTIA (ALS-FTD) NEUROPATHIES." THIS PROJECT WILL ADDRESS THE MOLECULAR MECHANISMS DRIVING DIVERSE ALS-FTD CAUSES. IN OCTOBER OF 2023, CHENXU ZHU, PHD, WHO HOLDS A JOINT APPOINTMENT AS AN NYGC CORE FACULTY MEMBER AND ASSISTANT PROFESSOR IN THE DEPARTMENT OF PHYSIOLOGY AND BIOPHYSICS AND THE INSTITUTE FOR COMPUTATIONAL BIOMEDICINE AT WEILL CORNELL MEDICINE, WAS AWARDED THE NATIONAL INSTITUTES OF HEALTH (NIH) DIRECTOR'S NEW INNOVATOR AWARD. DR. ZHU MARKS THE FOURTH NYGC CORE FACULTY MEMBER TO RECEIVE THE NIH DIRECTOR'S NEW INNOVATOR AWARD. NYGC IS THE RECIPIENT OF THE NIH COMMON FUND SOMATIC MOSAICISM ACROSS HUMAN TISSUES (SMAHT) NETWORK. THE AWARDED GRANTS OF $140 MILLION OVER FIVE YEARS FUND TWO RESEARCH PROJECTS LED BY SOREN GERMER, PHD, VICE PRESIDENT OF GENOME TECHNOLOGIES, SAM APARICIO, BM, BCH, PHD, FRCPATH, FRSC, SENIOR SCIENTIFIC DIRECTOR OF CANCER GENOMICS, DAN LANDAU, MD, PHD, NYGC CORE FACULTY MEMBER AND ASSOCIATE PROFESSOR OF MEDICINE IN THE DIVISION OF HEMATOLOGY AND MEDICAL ONCOLOGY AT WEILL CORNELL MEDICINE, AND RAHUL SATIJA, PHD, NYGC CORE FACULTY MEMBER AND ASSOCIATE PROFESSOR OF BIOLOGY AT NEW YORK UNIVERSITY. NYGC'S THOMAS LEHNER, PHD, MPH, GAMZE GRSOY, PHD, MIKE ZODY, PHD, CHARLES GAGNON, AND SHAILU GARGEYA RECEIVED AN AWARD FROM THE WARREN ALPERT FOUNDATION IN SUPPORT OF THE GENOMIC MEDICINE FOR MENTAL HEALTH ADVANCEMENT (GEMMA) DATA COMMONS PROJECT WHICH WILL SERVE AS A UNIQUE PLATFORM TO IMPLEMENT CLINICAL PREDICTION ALGORITHMS, THERAPEUTIC DISCOVERY EFFORTS, AND DATA-DRIVEN CLINICAL TRIAL ENROLLMENT. NYGC MADE GREAT PROGRESS IN CORE RESEARCH AREAS UNDER THE LEADERSHIP OF THE NEW YORK GENOME CENTER'S EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS, PHD. SELECT ACHIEVEMENTS INCLUDE: CANCER: EARLY IN 2023, NYGC LAUNCHED THE MACMILLAN CENTER FOR THE STUDY OF THE NON-CODING CANCER GENOME (CSNCG), A GROUNDBREAKING MULTI-DISCIPLINARY COLLABORATION BRINGING 23 INVESTIGATORS AND NINE INSTITUTIONS TOGETHER TO DEVELOP TECHNOLOGIES AND UNDERTAKE STUDIES AIMED AT UNDERSTANDING THE STRUCTURE AND FUNCTION OF THE NON-CODING GENOME AND EPIGENOME IN CANCER EVOLUTION, PROGRESSION, AND TREATMENT RESPONSE. THE MACMILLAN CENTER HAS A STRONG COMMITMENT TO OPEN SCIENCE AND COLLABORATION. ENABLED BY A GENEROUS LEAD GIFT FROM THE MACMILLAN FAMILY FOUNDATION, THE CSNCG HAS UNDERTAKEN THE GRAND CHALLENGE OF DECODING THE IMPACT OF THE NON-CODING GENOME IN CANCER BY CREATING AN END-TO-END DISCOVERY PLATFORM WITH EXPANSIVE RESEARCH EFFORTS, SPANNING FROM LARGE-SCALE MAPPING OF THE STRUCTURE AND FUNCTION OF DIVERSE CANCER GENOMES TO THE DEVELOPMENT OF NOVEL CELLULAR THERAPEUTICS AND DRUG DISCOVERY. THE CSNCG'S COLLABORATIVE APPROACH FOSTERS THE SHARING OF INFORMATION AND BREAKTHROUGHS WHICH POSITIONS THE CSNCG AS A CATALYST FOR TRANSFORMATIVE ADVANCEMENTS IN CANCER RESEARCH AND TREATMENT. |
| FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED) | ADDITIONALLY, IN 2023, A WORLD-CLASS RESEARCH TEAM LED BY MELISSA B. DAVIS, PHD, NYGC ASSOCIATE FACULTY AND POLYETHNIC-1000 (P-1000) CANCER ETHNICITY SCHOLAR AND THE DIRECTOR OF THE INSTITUTE OF TRANSLATIONAL GENOMIC MEDICINE AT MOREHOUSE SCHOOL OF MEDICINE, WAS SELECTED AS ONE OF FIVE INTERNATIONAL RESEARCH TEAMS TO RECEIVE UP TO $25M IN FUNDING FROM CANCER GRAND CHALLENGES. WITH THESE FUNDS, THE SAMBAI (SOCIETAL, ANCESTRY, MOLECULAR, AND BIOLOGICAL ANALYSES OF INEQUALITIES) TEAM WILL ADDRESS THE ISSUE OF INEQUITIES IN CANCER PREVENTION, SCREENING, AND TREATMENT BY: FOCUSING ON PROSTATE, BREAST, AND PANCREATIC CANCERS IN DIVERSE COHORTS OF AFRICAN DESCENT FROM REGIONS WITHIN AFRICA, THE UNITED KINGDOM, AND THE UNITED STATES. BUILDING AN UNPRECEDENTED RESOURCE COMPRISED OF COMPREHENSIVE MEASUREMENTS OF SOCIAL, ENVIRONMENTAL, GENETIC, AND BIOLOGICAL FACTORS USED TO HELP DEFINE THE CAUSES OF DISPARATE OUTCOMES IN THE SELECTED POPULATIONS. THE TEAM UNITES CLINICIANS, ADVOCATES, AND SCIENTISTS ACROSS FIFTEEN INSTITUTIONS AND SEVEN COUNTRIES WITH BROAD EXPERTISE IN EPIDEMIOLOGY, EXPOSOMICS, GENOMICS, IMMUNOLOGY, AND COMPUTATIONAL BIOLOGY. DR. NICOLAS ROBINE, DIRECTOR OF COMPUTATIONAL BIOLOGY AT NYGC, AND DR. MARCIN IMIELISKI, CORE FACULTY MEMBER AT NYGC AND DIRECTOR OF CANCER GENOMICS AT NYU LANGONE HEALTH'S PERLMUTTER CANCER CENTER, ARE WORKING ALONGSIDE OTHER GENOMICS COLLABORATORS TO PROCESS AND CONTEXTUALIZE LARGE AND COMPLEX DATA USING NOVEL ALGORITHMS, CLOUD COMPUTING, AND GRAPH REPRESENTATIONS OF REFERENCE SEQUENCES, WHICH ARE WELL-SUITED TO ANALYZE GENOMIC DATA OF PARTICIPANTS FROM DIVERSE ANCESTRIES. NEURODEGENERATIVE DISEASE: THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), LED BY NYGC CORE FACULTY MEMBER HEMALI PHATNANI, PHD, HAS ESTABLISHED A GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) CONSORTIUM, CONSISTING OF 42 MEMBER INSTITUTIONS WORLDWIDE. THE CGND HAS ALSO CONTRIBUTED TO ALS RESEARCH WITH THE DEVELOPMENT OF GENOMIC TECHNOLOGIES FOR THE STUDY OF RNA TRANSCRIPTION, SINGLE CELL TRANSCRIPTION, AND SPATIAL TRANSCRIPTOMICS. NYGC LEVERAGES THE SUCCESS OF OUR CGND'S FOCUS ON ALS RESEARCH TO EXTEND OUR WORK ACROSS A WIDER RANGE OF NEURODEGENERATIVE DISEASES THAT, DESPITE THEIR DIVERSE CLINICAL MANIFESTATIONS, SHARE COMMON PATHWAYS WITH ALS; SUCH DISEASES INCLUDE VASCULAR DEMENTIA, ALZHEIMER'S DISEASE, FRONTOTEMPORAL DEMENTIA (FTD), PARKINSON'S DISEASE, AND HUNTINGTON'S DISEASE. NYGC'S CGND RESEARCHERS HAVE BEEN WORKING WITH GLOBAL COLLABORATORS, UTILIZING NEW TECHNOLOGIES TO CREATE A MULTIDIMENSIONAL ATLAS OF GENE EXPRESSION IN ALS THAT PROVIDES NEW INSIGHTS INTO THE MECHANISMS THAT CONTRIBUTE TO DISEASE ONSET AND PROGRESSION. THESE BREAKTHROUGH FINDINGS ADVANCE THE UNDERSTANDING OF DISEASE MECHANISMS IN ALL NEURODEGENERATIVE DISEASES THAT SHARE COMMON PATHWAYS WITH ALS. NOTABLY, NYGC EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS AND NYGC CORE FACULTY MEMBER AND DIRECTOR OF THE NYGC'S CGND, HEMALI PHATNANI, HAVE BEEN WORKING CLOSELY WITH DAN DOCTOROFF AND TARGET ALS, ALONG WITH PARTNERS AT THE ALS ASSOCIATION GREATER NEW YORK CHAPTER, UNIVERSITY OF ROCHESTER MEDICAL CENTER, AND THE ELEANOR AND LOU GEHRIG ALS CENTER AT COLUMBIA UNIVERSITY TO ENCOURAGE NEW YORK STATE TO EXPAND SUPPORT FOR ALS RESEARCH IN NEW YORK. AS A RESULT OF THESE COLLABORATIVE EFFORTS, GOVERNOR HOCHUL RECENTLY ANNOUNCED A PLAN TO MAKE $25 MILLION IN STATE FUNDING AVAILABLE FOR ALS RESEARCH AND CARE - FUELING EARLY DIAGNOSIS EFFORTS, SCIENTIFIC STUDIES, AND DRUG DEVELOPMENT, AND PAVING THE WAY FOR MAJOR RESEARCH EFFORTS IN ALS, NEURODEGENERATIVE DISEASE, AND AGING IN NEW YORK STATE. |
| FORM 990, PART VI, SECTION A, LINE 2 | NYGC BOARD MEMBERS ELI CASDIN, ANTHONY EVNIN, THOMAS MANIATIS, JAMES SIMONS, AND NANCY THORNBERRY HAVE A BUSINESS RELATIONSHIP, EITHER DIRECTLY OR INDIRECTLY, THROUGH KALLYOPE, INC., A BIOTECHNOLOGY COMPANY DEVELOPING ORAL THERAPEUTICS AGAINST METABOLIC, NEUROLOGICAL, AND GASTROINTESTINAL DISEASES. NYGC HAS NOT CONDUCTED ANY BUSINESS WITH KALLYOPE, INC. |
| FORM 990, PART VI, SECTION A, LINE 6 | ORGANIZATION MEMBERS AS OF DECEMBER 31, 2023, THE CENTER HAD A TOTAL OF 13 MEMBERS, CONSISTING OF TEN INSTITUTIONAL FOUNDING MEMBERS AND THREE ASSOCIATE MEMBERS. THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) MEMORIAL SLOAN-KETTERING CANCER CENTER, (4) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (5) NEW YORK-PRESBYTERIAN HOSPITAL, (6) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (7) NORTHWELL HEALTH, (8) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (9) THE ROCKEFELLER UNIVERSITY, AND (10) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK. ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, AND (3) HACKENSACK MERIDIAN HEALTH. |
| FORM 990, PART VI, SECTION A, LINE 7A | ORGANIZATION MEMBERS - DECISION MAKING EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR/CEO AND INDEPENDENT DIRECTORS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS AND HAS THE DISCRETION TO MAKE CERTAIN DECISIONS WITHOUT FORMAL BOARD APPROVAL |
| FORM 990, PART VI, SECTION B, LINE 11B | FORM 990 REVIEW THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE CHIEF FINANCIAL OFFICER; DIRECTOR OF FINANCE; GENERAL COUNSEL; AND THE SCIENTIFIC DIRECTOR/CEO REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS |
| FORM 990, PART VI, SECTION B, LINE 12C | CONFLICT OF INTEREST POLICY & REVIEW NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, OFFICERS, AND KEY EMPLOYEES) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST DISCLOSED BY BOARD MEMBERS OR OFFICERS MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY PRESENT INFORMATION RELEVANT TO THE CONFLICT OF INTEREST OR UNDERLYING TRANSACTION AT A BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPENSATION REVIEW AND APPROVAL FFOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. FOR 2023, NYGC HIRED AN INDEPENDENT, OUTSIDE COMPENSATION CONSULTANT TO PERFORM AN ANALYSIS OF SENIOR MANAGEMENT'S TOTAL COMPENSATION. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO MEMBERS OF SENIOR MANAGEMENT WAS REASONABLE. THE COMPENSATION COMMITTEE OF THE BOARD (WHICH IS COMPOSED OF INDEPENDENT BOARD MEMBERS) MET AT A COMMITTEE MEETING HELD IN JANUARY 2023 AND APPROVED THE 2023 COMPENSATION TO BE PAID TO SENIOR MANAGEMENT. THE COMMITTEE DOCUMENTED ITS ACTIONS IN WRITTEN MEETING MINUTES. THE SENIOR MANAGEMENT TEAM RECEIVED STANDARD MERIT INCREASES IN 2023. MARIA JOANTA RECEIVED A SALARY INCREASE IN 2023 TO BRING HER SALARY CLOSER TO MARKET LEVELS AT THE RECOMMENDATION OF AN INDEPENDENT COMPENSATION CONSULTANT WHO PERFORMED AN EXECUTIVE TOTAL COMPENSATION STUDY FOR NYGC. THIS SALARY CHANGE WAS REVIEWED BY A COMPENSATION COMMITTEE OF INDEPENDENT BOARD MEMBERS AND APPROVED BY THE BOARD OF DIRECTORS. |
| FORM 990, PART VI, SECTION C, LINE 19 | NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART VII, SECTION A | IN 2023, TOM MANIATIS, PHD., SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAMS AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. DR. MANIATIS DEVOTES 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. |